Renal cell carcinoma (second line metastatic) - everolimus: appeal announcement

The Institute received two appeals from Novartis Pharmaceuticals and Kidney Cancer UK, plus one from James Whale Fund for Kidney Cancer which was rejected at scrutiny stage.

The appeal hearing took place at NICE, MidCity Place 71 High Holborn, London WC1V 6NA on Monday 28 February 2011 at 10am.

The Institute awaits the decision of the appeal panel.

Novartis : Written submission (PDF 98 KB)

Published:

24 February 2011
Novartis : Scrutiny letter (PDF 38 KB)

Published:

24 February 2011
Novartis : Response to scrutiny letter (PDF 60 KB)

Published:

24 February 2011
Novartis Appendix 1 : Response to scrutiny letter (PDF 27 KB)

Published:

24 February 2011
Novartis Appendix 2 : Response to scrutiny letter (PDF 18 KB)

Published:

24 February 2011
Novartis Appendix 3 : Response to scrutiny letter (PDF 40 KB)

Published:

24 February 2011
Novartis Appendix 3a : Response to scrutiny letter (PDF 137 KB)

Published:

24 February 2011
Novartis Appendix 3b : Response to scrutiny letter (PDF 65 KB)

Published:

24 February 2011
Novartis : Final scrutiny letter (PDF 26 KB)

Published:

24 February 2011
Kidney Cancer UK : Written submission (PDF 873 KB)

Published:

24 February 2011
Kidney Cancer UK : Scrutiny letter (PDF 23 KB)

Published:

24 February 2011
Kidney Cancer UK : Response to scrutiny letter (PDF 15 KB)

Published:

24 February 2011
Kidney Cancer UK : Final scrutiny letter (PDF 14 KB)

Published:

24 February 2011
James Whale Fund : Written submission (PDF 26 KB)

Published:

24 February 2011
James Whale Fund : Scrutiny letter (PDF 26 KB)

Published:

24 February 2011
James Whale Fund : Final scrutiny letter (PDF 14 KB)

Published:

24 February 2011

This page was last updated: 17 February 2017